West Pharmaceutical Services (WST) reported Q4 adjusted earnings Thursday of $1.82 per diluted share, down from $1.83 a year earlier.
Analysts polled by FactSet expected $1.72.
Revenue for the quarter ended Dec. 31 was $748.8 million compared with $732 million a year earlier.
Analysts surveyed by FactSet expected $740 million.
The company said it expects 2025 adjusted-diluted EPS to range from $6 to $6.20. Analysts surveyed by FactSet expect $7.45. The company expects revenue for the year to be $2.88 billion to $2.91 billion. Analysts polled by FactSet expect $3.04 billion.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。